| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,210,000 |
| Market
Cap: |
1.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.44 - $0.44 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Qualigen Therapeutics is a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Co.'s drug compound QN-302 is being developed to target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Co.'s anticancer drug candidate, QN-247 is aptamer-based and in development to treat a variety of cancer types, including liquid and solid tumors. Co.'s RAS-F portfolio is designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS and NRAS effector pathways.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
60,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$35,700 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Poirier Michael S. |
Chairman and CEO |
• • – |
2022-06-22 |
4 |
B |
$0.57 |
$17,100 |
D/D |
30,000 |
199,202 |
2.81 |
- |
|
| Broidrick Amy S. |
President/CSO |
• • – |
2022-06-14 |
4 |
B |
$0.62 |
$18,600 |
D/D |
30,000 |
34,500 |
2.81 |
- |
|
| Kruger Kurt H |
Director |
– • – |
2021-08-19 |
4 |
B |
$1.22 |
$9,800 |
D/D |
8,000 |
18,000 |
2.39 |
- |
|
| Broidrick Amy S. |
EVP, Chief Strategy Officer |
• • – |
2021-04-26 |
4 |
B |
$2.03 |
$9,135 |
D/D |
4,500 |
4,500 |
2.81 |
- |
|
| Poirier Michael S. |
Chairman, CEO & President |
• • – |
2021-04-20 |
4 |
B |
$1.80 |
$19,809 |
I/I |
11,005 |
11,005 |
2.58 |
- |
|
| Lotz Christopher L. |
Vice President of Finance, CFO |
• – – |
2021-04-16 |
4 |
B |
$1.86 |
$5,022 |
D/D |
2,700 |
12,541 |
2.74 |
- |
|
| Kruger Kurt H |
Director |
– • – |
2020-12-29 |
4 |
B |
$2.94 |
$11,740 |
D/D |
4,000 |
10,000 |
2.39 |
- |
|
| Emery Sidney W Jr |
Director |
– • – |
2020-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,682 |
|
- |
|
| Kruger Kurt H |
Director |
– • – |
2020-11-23 |
4 |
B |
$3.46 |
$15,925 |
D/D |
4,600 |
6,000 |
2.39 |
- |
|
| Kruger Kurt H |
Director |
– • – |
2020-11-20 |
4 |
B |
$3.55 |
$4,969 |
D/D |
1,400 |
1,400 |
2.31 |
- |
|
| Sekisui Diagnostics, Llc |
10% Owner |
– – • |
2020-05-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,980,233 |
|
- |
|
| Poirier Michael S. |
Chairman, President & CEO. |
• • – |
2020-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
169,192 |
169,192 |
|
- |
|
| Lotz Christopher L. |
VP of Finance, CFO. |
• – – |
2020-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,841 |
9,841 |
|
- |
|
| Foehr Matthew W |
Director |
– • – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
38,461 |
138,635 |
|
- |
|
| Doyle Noah |
Director |
– • – |
2020-03-12 |
4 |
S |
$0.22 |
$110,000 |
I/I |
(500,000) |
704,780 |
|
-97% |
|
| Ritter Andrew J |
CEO and President |
• • – |
2020-03-04 |
4 |
S |
$0.38 |
$7,043 |
I/I |
(18,750) |
81,727 |
|
2% |
|
| Ritter Ira E. |
COB, CSO |
• • – |
2020-03-04 |
4 |
S |
$0.38 |
$7,043 |
I/I |
(18,750) |
81,727 |
|
2% |
|
| Doyle Noah |
Director |
– • – |
2020-02-25 |
4 |
OE |
$0.15 |
$75,000 |
I/I |
500,000 |
1,204,780 |
|
- |
|
| Foehr Matthew W |
Director |
– • – |
2020-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
76,923 |
100,174 |
|
- |
|
| Foehr Matthew W |
Director |
– • – |
2018-08-17 |
4/A |
B |
$2.04 |
$40,292 |
D/D |
19,751 |
23,251 |
2.39 |
- |
|
| Foehr Matthew W |
Director |
– • – |
2018-08-17 |
4 |
B |
$2.04 |
$40,292 |
D/D |
19,751 |
54,751 |
2.39 |
- |
|
| Ritter Ira E. |
Exec. Chairman, CSO |
• • • |
2017-10-03 |
4 |
B |
$0.00 |
$0 |
I/I |
187,500 |
1,004,772 |
2.56 |
- |
|
| Javelin Venture Partners, L.p. |
10% Owner |
– – • |
2017-10-03 |
4 |
B |
$0.00 |
$0 |
D/D |
5,000,000 |
7,047,804 |
2.37 |
- |
|
| Ritter Andrew J |
President |
• – • |
2017-10-03 |
4 |
B |
$0.00 |
$0 |
I/I |
187,500 |
1,004,772 |
3.28 |
- |
|
| Doyle Noah |
Director |
– • • |
2017-10-03 |
4 |
B |
$0.00 |
$0 |
I/I |
5,000,000 |
7,047,804 |
2.17 |
- |
|
44 Records found
|
|
Page 1 of 2 |
|
|
